Hotline for Health Services for Displaced Lebanese 1787
Hotline for the Patient Admission to Hospitals 01/832700
COVID-19 Vaccine Registration Form covax.moph.gov.lb
MoPH Hotline 1214
Are you a new member? Sign up now
 
Let us help you
Read about the latest topics.

Hasbani Launched Hearing Screening National Awareness Campaign

 
Under the patronage of Deputy Prime Minister and Health Minister Ghassan Hasbani, the Ministry of Public Health launched “Hearing Screening National Awareness Campaign” under which hearing screening will be provided in six government hospitals for free for one month and at a lower cost after the campaign. It was also agreed with thirteen private hospitals to provide screening at lower costs during the campaign.

The campaign was attended by the UNICEF Representative in Lebanon Ms. Tanya Chapuisat, the head of the Association of Private Hospitals Sleiman Haroun, physicians and concerned parties.

Minister Hasbani stated that this campaign came to cover an important health topic for all the Lebanese and fell within the principle adopted by the Ministry, which is based on the fact that “an ounce of prevention is worth a pound of cure”. He went on saying that the Ministry is the only entity to cover cochlear implants. This campaign was launched with a focus on the government hospitals and a large number of private hospitals to contribute in hearing screening in infants for more than one reason: first, the human right to enjoy good health. Second: the importance of hearing at the economic level. In fact, we always talk about economic growth, investment in infrastructure, foreign and local investments…But unfortunately, many politicians and economists forget that the citizen is the key contributor to the economy. They also forget that the healthy citizen increases productivity over a long period of time.

Promedz’s director Mr. Hady Bsat noted the importance of the private-public sector cooperation, knowing that the campaign focuses on providing the Lebanese citizen with a better quality of life and a way to enhance his productivity. “If we could detect hearing impairment or loss and provide the necessary treatment at an earlier stage, the child is Likely to enroll in ordinary schools, without the need of special services or additional costs,” he added.
UNICEF Representative in Lebanon Ms. Tanya Chapuisat noted that hearing loss affects currently about 6 in 1000 children. The early detection makes parents aware of their child’s health and welfare.

Dr. Ammar

In his statement Director General Dr. walid Ammar stated that the report issued by the world health organization in march 2017 noted that untreated hearing loss takes its toll on the global economy.
    ...
    9
ATC Name B/G Ingredients Dosage Form Price
J01DD04 LEBACEF G Ceftriaxone - 1g 1g Injectable sterile powder for solution + lidocaine solvent 508,100 L.L
J01DD04 LEBACEF G Ceftriaxone - 1g 1g Injectable sterile powder for solution + lidocaine solvent 508,100 L.L
J01DD04 LEBACEF G Ceftriaxone (sodium) - 1g 1g Injectable powder for solution+diluent 508,100 L.L
J01DD04 LEBACEF G Ceftriaxone (sodium) - 1g 1g Injectable powder for solution 5,793,881 L.L
J01DD04 LEBACEF G Ceftriaxone (sodium) - 1g, Lidocaine (ampoule) - 1g Injectable powder for solution+diluent 568,253 L.L
J01DD04 LEBACEF G Ceftriaxone (sodium) - 1g 1g Injectable powder for solution+diluent 643,765 L.L
J01DD04 LEBACEF G Ceftriaxone (sodium) - 0.5g 0.5g Injectable powder for solution+diluent 511,940 L.L
J01DD04 LEBACEF G Ceftriaxone (sodium) - 0.5g 0.5g Injectable powder for solution+diluent 511,940 L.L
J01DD04 LEBACEF G Ceftriaxone (sodium) - 0.5g 0.5g Injectable powder for solution 3,455,595 L.L
J01DD04 LEBACEF G Ceftriaxone (sodium) - 0.5g, Lidocaine (ampoule) - 0.5g Injectable powder for solution+diluent 403,153 L.L
J01DD04 LEBACEF G Ceftriaxone (sodium) - 0.5g, Lidocaine (ampoule) - 0.5g Injectable powder for solution+diluent 403,153 L.L
J01DD04 LEBACEF G Ceftriaxone (sodium) - 0.5g 0.5g Injectable powder for solution+diluent 433,869 L.L
J01DD04 LEBACEF G Ceftriaxone (sodium) - 0.5g 0.5g Injectable powder for solution 3,455,595 L.L
J01DD04 LEBACEF G Ceftriaxone (sodium) - 0.5g 0.5g Injectable powder for solution+diluent 511,940 L.L
J01DD04 LEBACEF G Ceftriaxone (sodium) - 0.5g, Lidocaine (ampoule) - 0.5g Injectable powder for solution+diluent 511,940 L.L
C03CA01 LASIX B Furosemide - 500mg 500mg Tablet 1,454,038 L.L
C03CA01 LASIX B Furosemide - 40mg 40mg Tablet 120,946 L.L
C03CA01 LASIMIDE G Furosemide - 20mg/2ml 20mg/2ml Injectable solution 1,300,328 L.L
N05AE05 LAROZA G Lurasidone - 120mg 120mg Tablet, film coated 5,548,726 L.L
N05AE05 LAROZA G Lurasidone - 80mg 80mg Tablet, film coated 5,548,726 L.L
N05AE05 LAROZA G Lurasidone - 40mg 40mg Tablet, film coated 5,548,726 L.L
A10AE04 LANTUS SOLOSTAR BioTech Insulin glargine - 100IU/ml 100IU/ml Injectable solution 4,992,375 L.L
A10AE04 LANTUS BioTech Insulin glargine - 100IU/ml 100IU/ml Injectable solution 3,327,354 L.L
J07CA LANTIGEN B B Streptococcus pneumoniae type 3 (antigenic extracts) - 63.2A.U./ml, Streptococcus pyogenes group A (antigenic extracts) - 126.2A.U./ml, Branhamella catarrhalis (antigenic extracts) - 39.9A.U./ml, Staphylococcus aureus (antigenic extracts) - 79.6A.U./ml, Haemophilus influenzae type b (antigenic extracts) - 50.2A.U./ml, Klebsiella pneumoniae (antigenic extracts) - 39.8A.U./ml Drops suspension 916,501 L.L
C01AA05 LANOXIN PG B Digoxin - 0.05mg/ml 0.05mg/ml Elixir 307,740 L.L
C01AA05 LANOXIN B Digoxin - 0.25mg 0.25mg Tablet 215,015 L.L
N05AH02 LANOLEPT G Clozapine - 100mg 100mg Tablet 1,482,258 L.L
N03AX09 LAMOTRIGINE NORMON G Lamotrigine - 50mg 50mg Tablet, dispersible/ chewable 1,643,519 L.L
N03AX09 LAMOTRIGINE NORMON G Lamotrigine - 100mg 100mg Tablet, dispersible/ chewable 2,284,532 L.L
N03AX09 LAMOTRIGINE BIOGARAN G Lamotrigine - 50mg 50mg Tablet, dispersible 985,037 L.L
    ...
    9
Sitemap
© Copyrights reserved to Ministry of Public Health 2025